IMMUNOCOMPETENCE IN PATIENTS WITH HODGKIN'S DISEASE NLM AIDSLINE Important note: Information in this article was accurate in 1992. The state of the art may have changed since the publication date.

Click here to return to AIDSLINE main menu
DonateNow
Print this Article


IMMUNOCOMPETENCE IN PATIENTS WITH HODGKIN'S DISEASE

Hodgkin's Disease: The Consequences of Survival. Lacher MJ and Redman JR, eds. Philadelphia, Lea and Febiger, p. 112-50, 1990.. Unique Identifier : AIDSLINE ICDB/92680213
Bjorkholm M; Holm G; Mellstedt H; Div. of Hematology, Dept. of Medicine, Karolinska Hosp.,; Stockholm, Sweden

Abstract: Long-term survivors of Hodgkin's disease (HD) manifest certain late therapy-related complications. However, certain constitutional features of Hodgkin's patients (pts) may be manifested before any form of diagnostic or therapeutic intervention or they may develop in 'cured' pts without any relation to therapy. Consequently, these effects cannot be fully isolated in treated pts. Premorbid immunocompetence may be important in this context. Immunocompetence in pts with HD is reviewed under the following headings: untreated HD pts (blood lymphocyte subpopulations, blood lymphocyte functions, lymphocytes activated in vivo, clinical correlations of blood lymphocyte counts and functions, and antibody-mediated immunity), some confounding factors in studies of long-term survivors; effects of irradiation on the immune system (thymus irradiation, lymphocyte subpopulations, T-cell functions, nonlymphoid tumors, and non-Hodgkin's lymphoma); immunosuppressive effects of chemotherapeutic agents (lymphocyte subpopulations and functions and diseases other than lymphoma); delayed hypersensitivity, humoral immunity, and inflammatory reactions in HD (complement and phagocytic cells); lymphocytes activated in vivo following curative treatment in HD effects of splenectomy (lymphocyte subpopulations, lymphocyte functions, and serum Igs); effects of immunopotentiating therapy in untreated and treated pts with HD; immune functions of HD pts in remission following successful treatment; implications and consequences of immune deficit in disease-free Hodgkin's pts (pre- and post-treatment immune status in relation to prognosis, immunodeficiency and increased risk of second malignancies, and post-treatment immunodeficiency susceptibility to infection); mechanisms of the persistent T-cell defect in HD, lymphocyte maldistribution as a tentative mechanistic model of immunodeficiency in untreated and treated HD pts; immunologic studies in family members of pts with HD; immunologic impairment and the pathogenesis of HD; and a hypothesis relating immunodeficiency to etiology, tumor, and treatment. (383 Refs)
Keywords: Antibody Formation Bacterial Infections/ETIOLOGY CD4-CD8 Ratio Disease Susceptibility DNA/BIOSYNTHESIS Hodgkin's Disease/DRUG THERAPY/*IMMUNOLOGY/MORTALITY/RADIOTHERAPY Human Immune System/RADIATION EFFECTS Immune Tolerance/DRUG EFFECTS/RADIATION EFFECTS Immunity, Cellular *Immunocompetence Immunoglobulins/IMMUNOLOGY Leukocyte Count Lymphocyte Transformation Lymphoma, Non-Hodgkin's/IMMUNOLOGY Lymphopenia/ETIOLOGY Neoplasms, Second Primary Radiation Injuries Remission Induction Splenectomy T-Lymphocytes/IMMUNOLOGY/RADIATION EFFECTS Thymus Gland/RADIATION EFFECTS MONOGRAPHKWDantibodyformationbacterialinfections/etiologycd4-cd8ratiodiseasesusceptibilitydna/biosynthesishodgkin'sdisease/drugtherapy/KWDimmunology/mortality/radiotherapyhumanimmunesystem/radiationeffectsimmunetolerance/drugeffects/radiationeffectsimmunity,cellular
920630
M9261026

Copyright © 1992 - National Library of Medicine. Reproduced under license with the National Library of Medicine, Bethesda, MD.

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1992. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1992. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .